Tobramycin dosing in cystic fibrosis [5]

Lancet

Volumn 365, Issue 9473, 2005, Pages 1767-1768

  Smyth, Alan ^a   Touw, Daan ^b   Tan, Kelvin H V ^c   Bertenshaw, Carol ^c   Stableforth, David ^d  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b Apotheek Haagse Ziekenhuizen   (Netherlands)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; TOBRAMYCIN;

ACUTE KIDNEY FAILURE; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG DOSE REGIMEN; HUMAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPUTUM CULTURE;

EID: 19744372278     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66577-4     Document Type: Letter

References (5)

1. HL VandenBussche, ME Klepser Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs? Lancet 365 2005 547 548
2. A Smyth, KH-V Tan, P Hyman-Taylor Once versus three times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial Lancet 365 2005 573 578
3. DJ Touw Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis Pharm World Sci 20 1998 149 160
4. RD Bates, MC Nahata, JW Jones Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis Chest 112 1997 1208 1213
5. ML Barclay, EJ Begg, ST Chambers, PE Thornley, PK Pattemore, K Grimwood Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis J Antimicrob Chemother 37 1996 1155 1164